MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock from atm...
$20,668K
Proceeds from issuance of
common stock under the...
$450K
Proceeds from issuance of
common stock upon...
$4K
Net cash provided by
financing activities
$21,122K
Net change in cash
and cash...
-$21,379K
Canceled cashflow
$21,122K
Proceeds from maturities
of investments
$72,115K
Deposit placed in escrow
-$23,479K
Stock-based compensation
$8,270K
Depreciation and
amortization
$2,869K
Prepaid expenses and
other current assets
-$1,132K
Non-cash rent expense
$1,069K
Accounts payable
$663K
Other long-term
liabilities
$316K
Other long-term
assets
-$84K
Net cash provided by
(used in) investing...
-$29,588K
Canceled cashflow
$72,115K
Net cash used in
operating activities
-$12,913K
Canceled cashflow
$37,882K
Total operating
expenses
-$120,819K
Purchase of investments
$101,694K
Purchases of property and
equipment
$9K
Net loss
-$42,607K
Canceled cashflow
$120,819K
Accrued and other
current liabilities
-$5,101K
Operating lease
liabilities
-$2,202K
Net
amortization/accretion on investment...
$885K
something is missing
-$152,076K
Other income
(expenses), net
-$11,350K
Back
Back
Cash Flow
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)
source: myfinsight.com